zanubrutinib


( Last Updated : March 23, 2021)
Generic Name:
zanubrutinib
Project Status:
Pending
Therapeutic Area:
Waldenström’s macroglobulinemia
Manufacturer:
BeiGene, Ltd.
Call for patient/clinician input open:
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0248-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openMarch 23, 2021
Call for patient/clinician input closedMay 14, 2021
Clarification:

- Patient input submission received from CanCertainty and Lymphoma Canada (LC), Canadian Organization for Rare Disorders (CORD), Waldenstrom Macroglobulinemia Foundation of Canada (WMFC)

Submission receivedMay 21, 2021
Submission acceptedJune 07, 2021
Review initiatedJune 08, 2021
Draft CADTH review report(s) provided to sponsor for commentAugust 23, 2021
Deadline for sponsors commentsSeptember 01, 2021
CADTH responses on draft review report(s) provided to sponsorSeptember 30, 2021
Expert committee meeting (initial)October 13, 2021
Draft recommendation issued to sponsorOctober 25, 2021
To
October 27, 2021